| Name | 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide |
|---|---|
| Synonyms |
4-hydroxy-n-(4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl)-4-methyl-1-piperidinecarboxamide
4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide Tozadenant SYN-115 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-1,3-benzothiazol-2-yl]-4-methyl-1-piperidinecarboxamide 4-Hydroxy-N-(4-methoxy-7-morpholinobenzo(d)thiazol-2-yl)-4-methylpiperidine-1-carboxamide Tozadenant (USAN) 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide |
| Description | Tozadenant is an adenosine A2A receptor antagonist, with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. |
|---|---|
| Related Catalog | |
| Target |
Ki: 6 nM (Rhesus A2A), 11.5 nM (Human A2A) |
| In Vivo | 18F-MNI-444 regional uptake is consistent with A2A receptor distribution in the brain. Selectivity is demonstrated by dose-dependent blocking by tozadenant (1.5, 10.5 mg/kg) and preladenant[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C19H26N4O4S |
| Molecular Weight | 406.499 |
| Exact Mass | 406.167480 |
| PSA | 118.89000 |
| LogP | 0.43 |
| Index of Refraction | 1.662 |
| HS Code | 2934999090 |
|---|
|
~78%
870070-55-6 |
| Literature: Flohr, Alexander; Moreau, Jean-Luc; Poli, Sonia Maria; Riemer, Claus; Steward, Lucinda Patent: US2005/261289 A1, 2005 ; Location in patent: Page/Page column 7 ; US 20050261289 A1 |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |